| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial
|
Cook, Jonathan A
|
|
|
12 |
4 |
p. e294-e303
|
artikel
|
| 2 |
CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India
|
Paruzzo, Luca
|
|
|
12 |
4 |
p. e236-e238
|
artikel
|
| 3 |
CAR T-cell therapy: navigating real-world challenges beyond clinical trials
|
The Lancet Haematology,
|
|
|
12 |
4 |
p. e231
|
artikel
|
| 4 |
Celebrating 5 years of Women in Lymphoma: a road to equality, diversity, and inclusion in the field
|
Sureda, Anna
|
|
|
12 |
4 |
p. e246-e247
|
artikel
|
| 5 |
Cold-induced urticaria in multiple myeloma
|
Kwakernaak, Arjan J
|
|
|
12 |
4 |
p. e318
|
artikel
|
| 6 |
Correction to Lancet Haematol 2025; 12: e128–37
|
|
|
|
12 |
4 |
p. e243
|
artikel
|
| 7 |
Correction to Lancet Haematol 2025; 12: e120–27
|
|
|
|
12 |
4 |
p. e243
|
artikel
|
| 8 |
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial
|
Abboud, Miguel R
|
|
|
12 |
4 |
p. e248-e257
|
artikel
|
| 9 |
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study
|
Malpica, Luis
|
|
|
12 |
4 |
p. e258-e268
|
artikel
|
| 10 |
Establishment of a haematopoietic cell transplantation programme for children with sickle cell disease in Tanzania
|
Giglio, Fabio
|
|
|
12 |
4 |
p. e244-e245
|
artikel
|
| 11 |
Fedratinib for patients with myelofibrosis
|
Van Dijck, Ruben
|
|
|
12 |
4 |
p. e240
|
artikel
|
| 12 |
Fedratinib for patients with myelofibrosis
|
Le Grand, Sophie
|
|
|
12 |
4 |
p. e240-e241
|
artikel
|
| 13 |
Fedratinib for patients with myelofibrosis – Authors’ reply
|
Harrison, Claire N
|
|
|
12 |
4 |
p. e241-e242
|
artikel
|
| 14 |
Improving SARS-CoV-2 vaccine response is challenging in chronic lymphocytic leukaemia
|
Mauro, Francesca Romana
|
|
|
12 |
4 |
p. e238-e239
|
artikel
|
| 15 |
Monumen-TAL progress in the treatment of relapsed multiple myeloma
|
Bal, Susan
|
|
|
12 |
4 |
p. e235-e236
|
artikel
|
| 16 |
Now where do we STAND with crizanlizumab?
|
Mendez-Marti, Sebastian
|
|
|
12 |
4 |
p. e232-e233
|
artikel
|
| 17 |
Peripheral T-cell lymphoma in the Latin American population
|
Domingo Domenech, Eva
|
|
|
12 |
4 |
p. e233-e234
|
artikel
|
| 18 |
Quality-of-life endpoints collection, reporting, and framing in randomised trials of indolent lymphomas: a systematic review
|
Milrod, Charles J
|
|
|
12 |
4 |
p. e312-e317
|
artikel
|
| 19 |
Rising to the challenge: an international Delphi consensus study on fetal and neonatal alloimmune thrombocytopenia
|
Pothof, Romy
|
|
|
12 |
4 |
p. e304-e311
|
artikel
|
| 20 |
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
|
Chari, Ajai
|
|
|
12 |
4 |
p. e269-e281
|
artikel
|
| 21 |
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study
|
Jain, Hasmukh
|
|
|
12 |
4 |
p. e282-e293
|
artikel
|
Tijdschrift beschrijving